ReviewCancers2022

Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade.

Debottam Sinha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.